Prevnar (7 valent pneumococcal conjugate vaccine \[7vPnC\]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.
Infants who have completed the Prevnar 13 infant vaccination series who provide consent and fit the study inclusion criteria to participate in the study will be recruited.
Study Type
OBSERVATIONAL
Enrollment
239
To be performed as needed on children presenting with acute otitis media
To be performed at every study visit
Observational Study Only
Penfield Pediatrics
Penfield, New York, United States
Long Pond Pediatrics
Rochester, New York, United States
Legacy Pediatrics
Rochester, New York, United States
Lewis Pediatrics
Rochester, New York, United States
Percentage of Middle Ear Fluid (MEF) Samples With Positive Results for Streptococcus Pneumoniae Serotypes 1, 3, 5, 6A, 7F, or 19A in Participants With Acute Otitis Media (AOM)
MEF samples were obtained from participants who presented with an episode of AOM as defined by clinical criteria. Total percentage of MEF samples that were tested positive for any of the 6 additional serotypes included in Prevnar 13 (1, 3, 5, 6A, 7F, or 19A) have been reported.
Time frame: Baseline up to Month 36
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pathway Pediatrics
Rochester, New York, United States
Sunrise Pediatrics
Rochester, New York, United States
Westfall Pediatrics
Rochester, New York, United States